JUXTAPID 5 MG
LOMITAPIDE (LOMITAPIDE MESYLATE) : 5 MG · DIN 02420341 · CHIESI FARMACEUTICI S.P.A.
Health Canada status: MARKETED
What is JUXTAPID?
JUXTAPID 5 MG contains LOMITAPIDE (LOMITAPIDE MESYLATE) : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02420341, held by CHIESI FARMACEUTICI S.P.A., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JUXTAPID used for?
Adjunct to low-fat diet and other lipid-lowering drugs to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02420341 |
|---|---|
| Brand name | JUXTAPID |
| Generic / active ingredient | LOMITAPIDE (LOMITAPIDE MESYLATE) : 5 MG |
| Manufacturer | CHIESI FARMACEUTICI S.P.A. |
| Strength | 5 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AX12 LOMITAPIDE |
| AHFS class | 24:06.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Mar-2024 |
| Original market date | 2014-05-06 00:00:00 |
How is it administered?
Initial 5 mg daily. Titrate to 10, 20, 40, up to max 60 mg at min 4-week intervals based on safety/tolerability. Take without food, 2 hours after evening meal. Requires low-fat diet.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned in TOC but content not in snippet).
How is it supplied?
Bottles of 28 capsules.
Contraindications
Moderate/severe hepatic impairment; chronic bowel disease/malabsorption; strong/moderate CYP3A4 inhibitors; pregnancy; >20mg daily simvastatin; rare hereditary galactose/lactose issues.
Warnings and precautions
Risk of elevations in transaminases and hepatic steatosis. Severe diarrhea and dehydration. Potential for hepatotoxicity with alcohol or other hepatotoxic agents.
What can be used instead?
Other Canadian products sharing ATC code C10AX12 LOMITAPIDE. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JUXTAPID | 10 MG | CAPSULE | CHIESI FARMACEUTICI S.P.A. | MARKETED | DIN 02420376 |
| JUXTAPID | 20 MG | CAPSULE | CHIESI FARMACEUTICI S.P.A. | MARKETED | DIN 02420384 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.